Rola badań immunohistochemicznych w diagnostyce mięsaka gladkokomórkowego macicy


Author(s): Ewelina Wawryk-Gawda, Barbara Jodlowska-JÄ?drych

Uterine leiomyosarcoma is rare, representing 2- 6% of all uterine neoplasms. Most occur in women over 40 years of age. The histopathologic diagnosis is based on the microscopic constellation of hypercellularity, severe nuclear atypia, coagulative necrosis and high mitotic rate. Leiomyosarcoma is one of the mesenchymal tumors of the uterus. Into this group fall also endometrial stromal sarcoma, leiomyoma, smooth muscle tumour of uncertain malignant potential, malignant mixed Mullerian tumor and carcinosarcoma. The distinction between these tumors may at times be problematic cause of their similar microscopic building. It would be useful to have additional markers to distinguish among these neoplasms. Immunohistochemical studies of oncoproteins will undoubtedly lead to an accurate and prognostically relevant classification of these tumors. A lot of studies were undertaken to evaluate the utility of selected immunohistochemical markers in differentiating mesenchymal tumors. Results demonstrate that the significantly elevated expression of certain antigens (p53, Ki-67, Mdm2, MPM), may be useful to distinguish between cases of malignant smooth muscle tumors and those of borderline histology. Most types of uterine sarcomas have a poor prognosis. The conventional chemotherapy in leiomyosarcomas appears to be ineffective for some patients. In these women, new therapeutic strategies are warranted. Research demonstrate that uterine leiomyosarcomas express c-KIT, so the treatment with tyrosine kinase inhibitors in leiomyosarcoma patients might be hypothesized. Moreover leiomyosarcomas in occasional cases show positive staining for estrogen and progesterone receptors, hormonal manipulation in these cases may be helpful in controlling these tumors. Scientists suggest that clinical trials with innovative therapeutic method are needed in these aggressive and chemoresistant tumors.

Share this article

Editors List


    Submitted PhD thesis in Biotechnology at GITAM University, Vizag.

  • Yousef Alomi

    Yousef Alomi
    The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
    Saudi Arabia Critical Care/TPN
    Clinical Pharmacist Ministry of Health,
    Riyadh, Saudi Arabia.

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

Google Scholar citation report
Citations : 61

Onkologia i Radioterapia received 61 citations as per Google Scholar report

Onkologia i Radioterapia peer review process verified at publons
Indexed In
  • Scimago
  • MIAR
  • Euro Pub
  • Google Scholar
  • Medical Project Poland
  • Cancer Index
  • Gdansk University of Technology, Ministry Points 20